{"disease":{"id":"genetic-diseases-x-linked","name":"genetic diseases x linked"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03179631","title":"Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":360,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT03321604","title":"Kidney Information Network for Disease Research and Education","phase":"","overall_status":"TERMINATED","enrollment_count":338,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT01826487","title":"Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT02090959","title":"An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":219,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT03862950","title":"A Trial of Metformin in Individuals With Fragile X Syndrome (Met)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT03479476","title":"A Trial of Metformin in Individuals With Fragile X Syndrome","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT03876301","title":"Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants","phase":"","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Spark Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03406780","title":"A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Capricor Inc.","has_results":true},{"nct_id":"NCT00359411","title":"Genetic Studies of X-linked Lymphoproliferative Disease","phase":"","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03734588","title":"Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Spark Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07250737","title":"Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Avidity Biosciences, Inc.","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}